Sun Pharma Q1 net down 60% at Rs 478.96 cr

PTI New Delhi | Updated on January 23, 2018 Published on August 11, 2015

Drug major Sun Pharmaceutical Industries on Tuesday reported 60.23 per cent decline in consolidated net profit at Rs 478.96 crore for the April—June quarter due to one—time exceptional charges of Rs 685.17 crore related to write-downs and integration of Ranbaxy.

The company had posted a net profit of Rs 1,204.59 crore for the corresponding period of the previous fiscal.

Consolidated total income of the company rose to Rs 6,767.58 crore for the first quarter of 2015—16 as against Rs 6,341.21 crore in April—June 2014—15, the company said in a filing to the BSE.

The financials for the first quarter of this fiscal include several one—time and exceptional charges related to integration of Sun and Ranbaxy businesses, it said.

“Exceptional item for the quarter ended June 30, 2015 represents charge on account of impairment of fixed assets and other related costs and write down of the carrying value of goodwill on consolidation. This charge has arisen on account of the integration and optimisation exercises being carried out in certain manufacturing facilities,” Sun Pharma said.

Shares of Sun Pharmaceutical today closed at Rs 841.80 on BSE, up 0.03 per cent from previous close.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on August 11, 2015
This article is closed for comments.
Please Email the Editor